Expand all sections

Methotrexaat

Nordimet

Extended indication Extension of indication to include treatment of moderate to severe recalcitrant disabling psoriasis.
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Methotrexaat
Domain Chronic immune diseases
Reason of inclusion New medicine (specialité)
Main indication Skin diseases
Extended indication Extension of indication to include treatment of moderate to severe recalcitrant disabling psoriasis.
Proprietary name Nordimet
Manufacturer Nordic Pharma
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date November 2022
Expected Registration September 2023
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.